Literature DB >> 10817739

Activities of taurolidine in vitro and in experimental enterococcal endocarditis.

C Torres-Viera1, C Thauvin-Eliopoulos, M Souli, P DeGirolami, M G Farris, C B Wennersten, R D Sofia, G M Eliopoulos.   

Abstract

In vitro, the antimicrobial agent taurolidine inhibited virtually all of the bacteria tested, including vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and Stenotrophomonas maltophilia, at concentrations between 250 and 2,000 microg/ml. Taurolidine was not effective in experimental endocarditis. While it appears unlikely that this antimicrobial would be useful for systemic therapy, its bactericidal activity and the resistance rates found (<10(-9)) are favorable indicators for its possible development for topical use.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10817739      PMCID： PMC89943          DOI： 10.1128/AAC.44.6.1720-1724.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.

Authors:  T Schülin; C Thauvin-Eliopoulos; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Taurolin, a new chemotherapeutic agent.

Authors:  M K Browne; G B Leslie; R W Pfirrmann
Journal:  J Appl Bacteriol       Date:  1976-12

3.  Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin.

Authors:  R G Hindes; S H Willey; G M Eliopoulos; L B Rice; C T Eliopoulos; B E Murray; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

4.  Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells.

Authors:  I Bedrosian; R D Sofia; S M Wolff; C A Dinarello
Journal:  Cytokine       Date:  1991-11       Impact factor: 3.861

5.  Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery.

Authors:  D M Baker; J A Jones; J S Nguyen-Van-Tam; J H Lloyd; D L Morris; J B Bourke; R J Steele; J D Hardcastle
Journal:  Br J Surg       Date:  1994-07       Impact factor: 6.939

6.  In-vitro antibacterial activity of noxythiolin and taurolidine.

Authors:  J I Blenkharn
Journal:  J Pharm Pharmacol       Date:  1990-08       Impact factor: 3.765

7.  Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent.

Authors:  S P Gorman; D F McCafferty; A D Woolfson; D S Jones
Journal:  J Appl Bacteriol       Date:  1987-04

8.  Taurolidine: in vitro activity against multiple-antibiotic-resistant, nosocomially significant clinical isolates of Staphylococcus aureus, Enterococcus faecium, and diverse Enterobacteriaceae.

Authors:  W H Traub; B Leonhard; D Bauer
Journal:  Chemotherapy       Date:  1993 Sep-Oct       Impact factor: 2.544

9.  In vitro activity of taurolidine, chlorophenol-camphor-menthol and chlorhexidine against oral pathogenic microorganisms.

Authors:  M Zimmermann; V Preac-Mursic
Journal:  Arzneimittelforschung       Date:  1992-09

10.  Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled, double-blind trial.

Authors:  S M Willatts; S Radford; M Leitermann
Journal:  Crit Care Med       Date:  1995-06       Impact factor: 7.598
  10 in total
  12 in total

1.  Comparative in vitro efficacies of various catheter lock solutions.

Authors:  Robert J Sherertz; Michael S Boger; Casey A Collins; Lori Mason; Issam I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  Antimicrobial activity of a novel catheter lock solution.

Authors:  Chirag B Shah; Marc W Mittelman; J W Costerton; Stephen Parenteau; Michael Pelak; Richard Arsenault; Leonard A Mermel
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Taurolidine antiadhesive properties on interaction with E. coli; its transformation in biological environment and interaction with bacteria cell wall.

Authors:  Francesco Caruso; James W Darnowski; Cristian Opazo; Alexander Goldberg; Nina Kishore; Elin S Agoston; Miriam Rossi
Journal:  PLoS One       Date:  2010-01-28       Impact factor: 3.240

4.  Taurolidine lock solution for catheter-related bloodstream infections in pediatric patients: A meta-analysis.

Authors:  Yan Sun; Guanghui Wan; Liping Liang
Journal:  PLoS One       Date:  2020-04-07       Impact factor: 3.240

Review 5.  Antineutrophil cytoplasmic antibody-positive infective endocarditis complicated by acute kidney injury: a case report and literature review.

Authors:  Wei Zhang; Hui Zhang; Daoxu Wu; Haiyang Fu; Weiping Shi; Feng Xue
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

6.  Substitution of citrate with tissue plasminogen activator (rt-PA) for catheter lock does not improve patency of tunnelled haemodialysis catheters in a randomised trial.

Authors:  Pavlina Richtrova; Jan Mares; Lukas Kielberger; Jan Klaboch; Jaromir Eiselt; Tomas Reischig
Journal:  BMC Nephrol       Date:  2021-01-28       Impact factor: 2.388

7.  The best solution down the line: an observational study on taurolidine- versus citrate-based lock solutions for central venous catheters in hemodialysis patients.

Authors:  Sonja van Roeden; Mathijs van Oevelen; Alferso C Abrahams; Friedo W Dekker; Joris I Rotmans; Sabine C A Meijvis
Journal:  BMC Nephrol       Date:  2021-09-13       Impact factor: 2.388

8.  Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients.

Authors:  Arne Simon; Roland A Ammann; Gertrud Wiszniewsky; Udo Bode; Gudrun Fleischhack; Mette M Besuden
Journal:  BMC Infect Dis       Date:  2008-07-29       Impact factor: 3.090

Review 9.  Taurolidine lock solutions for the prevention of catheter-related bloodstream infections: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yong Liu; An-Qiang Zhang; Lin Cao; Hong-Tao Xia; Jun-Jie Ma
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

Review 10.  Bench-to-bedside review: Challenges of diagnosis, care and prevention of central catheter-related bloodstream infections in children.

Authors:  Susanne Janum; Walter Zingg; Volker Classen; Arash Afshari
Journal:  Crit Care       Date:  2013-08-28       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.